Susan M. O’Brien, MD, discusses the challenges with the 3 oral agents approved in chronic lymphocytic leukemia.
Susan M. O’Brien, MD, associate director for clinical sciences, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, discusses the challenges with the 3 oral agents approved in chronic lymphocytic leukemia (CLL).
Ibrutinib (Imbruvica) is the only agent approved in the frontline setting currently, but venetoclax (Venclexta) is now being investigated in a randomized clinical trial with obinutuzumab (Gazyva), another novel anti-CD20 monoclonal antibody, O’Brien says. Based on that data, there may be more options for the frontline treatment of CLL, but it would make sequencing more complicated.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More